Efficacy of desvenlafaxine succinate for menopausal hot flashes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: The concern for the development of breast cancer, stroke, cardiovascular disease and deep venous thrombosis with the use of hormonal therapy has led to the development of alternative nonhormonal forms of therapy like desvenlafaxine for the management of hot flashes.Areas covered: This review is based upon a PubMed search and clinical trials. The pharmacokinetics and pharmacodynamics of desvenlafaxine are reviewed. This review outlines the effects of desvenlafaxine in management of severity and frequency of vasomotor symptoms, sleep quality and quality of life in postmenopausal women. The potential adverse effects of desvenlafaxine are summarized.Expert opinion: Based on the evidence from randomized clinical trials, desvenlafaxine is an alternate viable option for reducing the frequency and severity of hot flashes when other treatments fail. In clinical trials, it has been shown that desvenlafaxine reduced the frequency of hot flashes by 55-69%. In the trials so far it appears to have good safety and tolerability profile when the drug is initiated in titrating doses. The optimum dose is 100 mg/day and is to be started at 50 mg/day for 3 days and titrated to 100 mg/day. The most common adverse events reported were nausea, dry mouth, fatigue, constipation, diarrhea and somnolence.

Original languageEnglish
Pages (from-to)2407-2418
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number16
DOIs
StatePublished - Nov 1 2014

Fingerprint

Hot Flashes
Clinical Trials
Expert Testimony
Constipation
PubMed
Venous Thrombosis
Nausea
Fatigue
Mouth
Desvenlafaxine Succinate
Diarrhea
Sleep
Cardiovascular Diseases
Therapeutics
Randomized Controlled Trials
Pharmacokinetics
Stroke
Quality of Life
Breast Neoplasms
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Efficacy of desvenlafaxine succinate for menopausal hot flashes. / Tella, Sri Harsha; Gallagher, John Christopher G.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 16, 01.11.2014, p. 2407-2418.

Research output: Contribution to journalArticle

@article{bd93b21043824cdf8aa7d713eb818ec1,
title = "Efficacy of desvenlafaxine succinate for menopausal hot flashes",
abstract = "Introduction: The concern for the development of breast cancer, stroke, cardiovascular disease and deep venous thrombosis with the use of hormonal therapy has led to the development of alternative nonhormonal forms of therapy like desvenlafaxine for the management of hot flashes.Areas covered: This review is based upon a PubMed search and clinical trials. The pharmacokinetics and pharmacodynamics of desvenlafaxine are reviewed. This review outlines the effects of desvenlafaxine in management of severity and frequency of vasomotor symptoms, sleep quality and quality of life in postmenopausal women. The potential adverse effects of desvenlafaxine are summarized.Expert opinion: Based on the evidence from randomized clinical trials, desvenlafaxine is an alternate viable option for reducing the frequency and severity of hot flashes when other treatments fail. In clinical trials, it has been shown that desvenlafaxine reduced the frequency of hot flashes by 55-69{\%}. In the trials so far it appears to have good safety and tolerability profile when the drug is initiated in titrating doses. The optimum dose is 100 mg/day and is to be started at 50 mg/day for 3 days and titrated to 100 mg/day. The most common adverse events reported were nausea, dry mouth, fatigue, constipation, diarrhea and somnolence.",
author = "Tella, {Sri Harsha} and Gallagher, {John Christopher G.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1517/14656566.2014.964641",
language = "English",
volume = "15",
pages = "2407--2418",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "16",

}

TY - JOUR

T1 - Efficacy of desvenlafaxine succinate for menopausal hot flashes

AU - Tella, Sri Harsha

AU - Gallagher, John Christopher G.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Introduction: The concern for the development of breast cancer, stroke, cardiovascular disease and deep venous thrombosis with the use of hormonal therapy has led to the development of alternative nonhormonal forms of therapy like desvenlafaxine for the management of hot flashes.Areas covered: This review is based upon a PubMed search and clinical trials. The pharmacokinetics and pharmacodynamics of desvenlafaxine are reviewed. This review outlines the effects of desvenlafaxine in management of severity and frequency of vasomotor symptoms, sleep quality and quality of life in postmenopausal women. The potential adverse effects of desvenlafaxine are summarized.Expert opinion: Based on the evidence from randomized clinical trials, desvenlafaxine is an alternate viable option for reducing the frequency and severity of hot flashes when other treatments fail. In clinical trials, it has been shown that desvenlafaxine reduced the frequency of hot flashes by 55-69%. In the trials so far it appears to have good safety and tolerability profile when the drug is initiated in titrating doses. The optimum dose is 100 mg/day and is to be started at 50 mg/day for 3 days and titrated to 100 mg/day. The most common adverse events reported were nausea, dry mouth, fatigue, constipation, diarrhea and somnolence.

AB - Introduction: The concern for the development of breast cancer, stroke, cardiovascular disease and deep venous thrombosis with the use of hormonal therapy has led to the development of alternative nonhormonal forms of therapy like desvenlafaxine for the management of hot flashes.Areas covered: This review is based upon a PubMed search and clinical trials. The pharmacokinetics and pharmacodynamics of desvenlafaxine are reviewed. This review outlines the effects of desvenlafaxine in management of severity and frequency of vasomotor symptoms, sleep quality and quality of life in postmenopausal women. The potential adverse effects of desvenlafaxine are summarized.Expert opinion: Based on the evidence from randomized clinical trials, desvenlafaxine is an alternate viable option for reducing the frequency and severity of hot flashes when other treatments fail. In clinical trials, it has been shown that desvenlafaxine reduced the frequency of hot flashes by 55-69%. In the trials so far it appears to have good safety and tolerability profile when the drug is initiated in titrating doses. The optimum dose is 100 mg/day and is to be started at 50 mg/day for 3 days and titrated to 100 mg/day. The most common adverse events reported were nausea, dry mouth, fatigue, constipation, diarrhea and somnolence.

UR - http://www.scopus.com/inward/record.url?scp=84911470993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911470993&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.964641

DO - 10.1517/14656566.2014.964641

M3 - Article

VL - 15

SP - 2407

EP - 2418

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -